Valiant Organics Ltd

- FY25 revenue expected in the range of INR 900-1000 crores, with conservative estimates due to current market conditions. - Growth of approximately 40% anticipated in FY25 driven by volume improvement in PAP and new Pharma Intermediates and chlorophenol products. - Incremental revenue of around INR 200 crores expected from PAP at full capacity (~600-700 tons/month targeted by year-end). - Pharma Intermediates expected to contribute approximately INR 70-80 crores, with launch of eight new products planned early FY25. - OAP products likely to add INR 20-30 crores. - Capacity expansions have increased overall production capabilities significantly since 2020, with about 2000 MT added annually excluding PAP. - Market prices are subdued largely due to China dumping and global slowdown, but demand turnaround and new product launches expected to drive volumes and revenue growth beyond FY25. - Target EBITDA margin post expansion aimed upward of 20% by FY26 with innovation and product additions.

- FY25 revenue target: INR 900-1000 crores, with conservative growth given current market pricing and demand conditions. - New products like Pharma Intermediates, OAP, and chlorophenol expected to contribute around INR 280-300 crores incremental revenue. - Aim for EBITDA margin upwards of 20% over the next two years, though FY25 margins might be below 20% due to subdued prices. - Volume growth expected from PAP reaching 600-700 tons/month and addition of new customers. - Debt repayment outflow around INR 40-50 crores in FY25, with some loans retiring in September and February. - Capacity expanded significantly since 2020, supporting volume growth and better margins when market normalizes. - Management optimistic of higher EBITDA base post-market recovery due to expansions and product innovations. - Payback period for investments extended due to current price pressures but expected to improve with market stabilization.

The transcript does not explicitly mention the current or expected order book or pending orders for Valiant Organics Limited. However, some relevant insights related to demand and orders include: - There has been subdued demand and pressure on pricing due to global slowdown and China dumping. - PAP (Paracetamol) sales averaged 119 MT per month initially, with a surge to 370 MT in December, indicating improving demand. - Management expects FY25 to be significantly better due to volume growth in PAP and new Pharma Intermediate projects. - Expansion efforts and capacity increases are underway, with PAP expected to scale up to around 600-700 MT by year-end. - Marketing efforts continue to onboard more customers, which is currently the limiting factor in capacity utilization, especially in chlorination segment. No clear, specific figures for pending or order backlog were disclosed in the call.

- As of the Q3 FY24 earnings call in February 2024, Valiant Organics Limited has not indicated any immediate large-scale capital expenditure or fundraising plans through debt or equity for FY25. - The company mentioned standard maintenance CapEx of around INR 30-40 crores for FY25 but no major new projects yet; decisions on significant CapEx might be made in the second half of the current year. - Regarding term loan repayments, the company expects an outflow of about INR 40-50 crores in FY25 as two loans will retire (one in September, the other in February). - No explicit mention was made about raising new debt or equity capital during the call. - The company seems to be focusing on operational cash flows and repayments rather than raising fresh funds in the near term.

- For FY25, Valiant Organics does not plan any large or significant CapEx, only standard maintenance CapEx of around INR 30-40 crores. - Any major CapEx decisions will be considered based on how the current year unfolds, potentially planned in the second half of the year for subsequent years. - No immediate major capital investment is planned until market conditions stabilize, especially given the current pricing pressures. - The company is focusing on scaling new products (like Pharma Intermediates, chlorophenol) rather than heavy CapEx projects. - Newer products in chlorophenol are expected to add to the product portfolio starting Q1 of the next fiscal year. - Two term loans are scheduled for retirement in FY25 (one in September, one in February), indicating some debt repayment outflows but no new large debt-financed investments mentioned.